The new report by Expert Market Research titled, ‘Global Hereditary Angioedema Therapeutic Market Analysis, Size, Share, Price, Trends, Report, Forecast 2023-2028’, gives in-depth analysis of the Global Hereditary Angioedema Therapeutic Market, assessing the market based on its segments like categorised, treatment types, route of administration, and major regions.
The report tracks the latest trends in the industry and studies their impact on the overall market. It also assesses the market dynamics, covering the key demand and price indicators, along with analyzing the market based on the SWOT and Porter’s Five Forces models.
Request a free sample copy in PDF or view the report summary@ https://www.expertmarketresearch.com/reports/hereditary-angioedema-therapeutic-market/requestsample
The key highlights of the report include:
Market Overview (2018-2028)
- Historical Market Size (2020): USD 2.7 Billion
- Forecast CAGR (2023-2028): 8.7%
- Forecast Market Size (2026): USD 4.5 Billion
The growing awareness-raising actions among the general community are driving the hereditary angioedema treatment market. The main cause of misdiagnosis is a lack of understanding of hereditary angioedema therapeutics, which leads to patients receiving inadequate therapy. Appendicitis, gastrointestinal issues, and other non-allergic angioedema illnesses are misdiagnosed in some people with hereditary angioedema.
A vast pool of individuals with high medical demands is created by a small number of patients misdiagnosed for the condition. In the coming years, this is projected to be a major market driver for hereditary angioedema therapeutics.
Hereditary Angioedema Therapeutic Industry Definition and Major Segments
Hereditary angioedema is a rather uncommon hereditary condition. Repeated episodes of significant swelling of the limbs, digestive system, face, and airway are common symptoms of the condition. There are three different types of this disease: Type I HAE, Type II HAE, and Type III HAE are the three types of HAE.
Explore the full report with the table of contents@ https://www.expertmarketresearch.com/reports/hereditary-angioedema-therapeutic-market
The industry can be broadly categorised based on drug class into:
- C1-Esterase Inhibitor
- Bradykinin B2 Receptor Antagonist
- Kallikrein Inhibitor
The industry can be divided based on treatment types as:
- Prophylaxis Treatment
- On-Demand Treatment
The industry can be classified based on the route of administration:
Based on region, the market is segmented into:
- North America
- Asia Pacific
- Latin America
- Middle East and Africa
Hereditary Angioedema Therapeutic Market Trends
The global increase in incidence of hereditary angioedema (HAE) is a major market driver. According to the National Organization for Rare Disorders (NORD), the illness affects 1-9 persons per 100,000 people. Because of under-reporting and misdiagnosis, the true number of people with the disease is far greater. Misdiagnosis is common due to a lack of knowledge regarding HAE, which results in patients receiving poor therapy. Most people with hereditary angioedema are misdiagnosed as having appendicitis, gastrointestinal problems, or other non-allergic angioedema. A large number of people have been misdiagnosed for the ailment, resulting in a large patient pool with significant medical demands. This will very certainly be a major driving force in the market.
Another aspect contributing to the market’s growth is the rise of activities aimed at raising public awareness. The initiative’s goal is to help patients get a faster diagnosis and receive the best treatment and care possible. To meet the significant unmet medical need, pharmaceutical drug companies are increasingly focusing on developing innovative therapies for hereditary angioedema. Because of new product releases by major companies, a superior reimbursement scenario, and well-developed healthcare infrastructure, North America led the market in terms of revenue.
The FDA, for example, gave regulatory approval for Cinryze for expanded use in paediatric patients aged 6 and up. During the projected period, Asia Pacific is predicted to grow at the fastest rate. The market in the region is likely to be driven by rising patient awareness and the introduction of newer medicines for the treatment of hereditary angioedema.
Key Market Players
The major players in the market are Shire Plc (Takeda), BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX), Ionis Pharmaceuticals, Inc., Pharming Group N.V., CSL Limited, Attune Pharmaceuticals, Inc., Adverum Biotechnologies, Inc., among others. The report covers the market shares, capacities, plant turnarounds, expansions, investments and mergers and acquisitions, among other latest developments of these market players.
Read More Reports:-
Expert Market Research (EMR) is leading market research company with clients across the globe. Through comprehensive data collection and skilful analysis and interpretation of data, the company offers its clients extensive, latest and actionable market intelligence which enables them to make informed and intelligent decisions and strengthen their position in the market. The clientele ranges from Fortune 1000 companies to small and medium scale enterprises.
EMR customises syndicated reports according to clients’ requirements and expectations. The company is active across over 15 prominent industry domains, including food and beverages, chemicals and materials, technology and media, consumer goods, packaging, agriculture, and pharmaceuticals, among others.
Over 3000 EMR consultants and more than 100 analysts work very hard to ensure that clients get only the most updated, relevant, accurate and actionable industry intelligence so that they may formulate informed, effective and intelligent business strategies and ensure their leadership in the market.
Company Name: Claight Corporation
Contact Person: John Walker, Corporate Sales Specialist – U.S.A.
Toll Free Number: +1-415-325-5166 | +44-702-402-5790
Address: 30 North Gould Street, Sheridan, WY 82801, USA